Zheng Wei, Zhang Xin-Yang, Xu Rui, Huang Xiong, Zheng Ying-Jun, Huang Xing-Bing, Li Ze-Zhi, Chen Huo-Di
The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Laboratory of Laser Sports Medicine, School of Sports Science, South China Normal University, Guangzhou, China.
Front Aging Neurosci. 2022 Oct 24;14:1036676. doi: 10.3389/fnagi.2022.1036676. eCollection 2022.
We performed this systemic review to investigate the therapeutic potential and safety of adjunctive accelerated repetitive transcranial magnetic stimulation (aTMS) for older patients with depression.
We included published randomized clinical trials (RCTs) and observational studies targeting adjunctive aTMS for older patients with depression.
Two open-label self-controlled studies ( = 29) fulfilled the criteria for inclusion. The included studies reported significant improvements in depressive symptoms from baseline to post-aTMS (all < 0.05). One study reported a dropout rate of 10.5% (2/19). Mild headache was the most common adverse reaction.
The currently available evidence from two open-label self-controlled studies indicates that adjunctive aTMS is a safe and effective therapy for older patients with depression.
我们进行了这项系统评价,以研究辅助性加速重复经颅磁刺激(aTMS)治疗老年抑郁症患者的潜在疗效和安全性。
我们纳入了已发表的针对老年抑郁症患者辅助性aTMS的随机临床试验(RCT)和观察性研究。
两项开放标签自我对照研究(n = 29)符合纳入标准。纳入的研究报告称,从基线到aTMS治疗后,抑郁症状有显著改善(均P < 0.05)。一项研究报告的脱落率为10.5%(2/19)。轻度头痛是最常见的不良反应。
两项开放标签自我对照研究的现有证据表明,辅助性aTMS是治疗老年抑郁症患者的一种安全有效的疗法。